3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)-
- CAS No.
- 2240191-12-0
- Chemical Name:
- 3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)-
- Synonyms
- BCR-ABL-IN-3;3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)-
- CBNumber:
- CB79834780
- Molecular Formula:
- C20H17ClF2N4O3S
- Molecular Weight:
- 466.89
- MDL Number:
- MOL File:
- 2240191-12-0.mol
- MSDS File:
- SDS
3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)- Chemical Properties, Uses, Production
Uses
BCR-ABL-IN-3 is a potent and irreversible Bcr-Abl inhibitor with an IC50 of ≤100 nM for Ba/F3Bcr-AblT3151. BCR-ABL-IN-3 has anti-cancer activity[1].
in vivo
BCR-ABL-IN-3 (compound 7; 15 mg/kg; twice a day; for 19 days) has good antitumor effect in female NOD/SCID mice of 7-8 weeks weighing 21.8 g with Ba/F3Bcr-AblT3151 cells[1].
BCR-ABL-IN-3 (2 mg/kg for IV or 20mg/kg for PO) has a Cmax of 5485 ng/mL and an AUC of 5450 hng/mL for IV in male Sprague Dawley rats of 7-8 weeks old weighing 210 g[1].
IC 50
Ba/F3Bcr-AblT3151: ≤100 nM (IC50)
References
[1] Hanyi Wang, et al. (hetero)arylamide compound for inhibiting protein kinase activity. WO2018133826A1.
3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)- Preparation Products And Raw materials
Raw materials
Preparation Products
3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(4-isothiazolyl)- Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 16314854226; +8616314854226 | inquiry@bocsci.com | United States | 19852 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29874 | 58 |
| Supplier | Advantage |
|---|---|
| BOC Sciences | 58 |
| TargetMol Chemicals Inc. | 58 |




